NASDAQ: CNTX
Context Therapeutics Inc Stock Ownership - Who owns Context Therapeutics?

Insider buying vs selling

Have Context Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Martin A. LehrChief Executive Officer2025-06-09100,000$0.70
$70.10kBuy
Alex C. LevitChief Legal Officer Corp. Sec2025-06-0620,000$0.58
$11.52kBuy
Jennifer Lynn MinaiazaryChief Financial Officer2025-06-0640,010$0.64
$25.49kBuy

1 of 1

CNTX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CNTX insiders and whales buy or sell their stock.

CNTX Shareholders

What type of owners hold Context Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Mpm Bioimpact LLC16.39%14,705,882$9.25MInstitution
Avidity Partners Management LP8.34%7,477,200$4.70MInstitution
Deep Track Capital LP8.27%7,419,355$4.67MInstitution
Nextech Invest Ltd8.27%7,419,355$4.67MInstitution
Blue Owl Capital Holdings LP8.21%7,367,906$4.63MInstitution
Great Point Partners LLC5.22%4,683,711$2.95MInstitution
Franklin Resources Inc4.46%4,003,380$2.52MInstitution
Vanguard Group Inc3.63%3,253,467$2.05MInstitution
Blackstone Inc2.72%2,440,330$1.53MInstitution
Nantahala Capital Management LLC2.16%1,935,484$1.22MInstitution

1 of 3

CNTX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CNTX79.60%1.46%Net BuyingNet Buying
PMVP57.32%42.68%Net Buying
ANEB41.32%58.68%Net Buying
XCUR0.50%99.50%Net BuyingNet Selling
NRSN0.84%0.00%

Context Therapeutics Stock Ownership FAQ

Who owns Context Therapeutics?

Context Therapeutics (NASDAQ: CNTX) is owned by 79.60% institutional shareholders, 1.46% Context Therapeutics insiders, and 18.93% retail investors. Martin A. Lehr is the largest individual Context Therapeutics shareholder, owning 1.08M shares representing 1.20% of the company. Martin A. Lehr's Context Therapeutics shares are currently valued at $679.25k.

If you're new to stock investing, here's how to buy Context Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.